Quit Genius has been added to the insurer space with the new Evry Health operation

Quit Genius is diving into the payoff for a new partnership with B2B insurance company Evry Health. As part of the agreement, Dallas -based members of Evry Health will have access to Quit Genius digital services, which include tobacco, alcohol and opioid addiction management.

This move is part of Quit Genius ’larger plan to expand the pay market.

“Payers are at the heart of our go-to-market strategy. We’re partnering with payers across the country to do Genius leaves an option in the system, providing a financial model that meets the needs of the payer and their investment plan.

“Financial management models based on performance assurance and crisis management continue to be an important model to ensure economic success to our partners,” said Drs. Yusuf Sherwani, cofounder and CEO of Quit Genius, wrote in an email to MobiHealthNews.

Under the agreement, Quit Genius digital tools will become part of Evry Health’s personal health plans, regardless of cost to the manufacturer or employee. Quit Genius can be applied to members who are using a healing room or detoxification services. Members can register themselves.

“Our care strategy allows us to drive significant costs for the paying population by increasing the participation of program members in SUD care before their care journey. to drive suppliers with the best results, ”Sherwani said.

Why it is

Opioid addiction continues in the US The CDC reported that 1.6 million people contracted opioid addiction in the past year. By 2019, more than 70,000 people will die from drug overdoses, according to the industry.

During COVID-19 disease, alcohol use increased. According to research published in Hepatology by a team at Massachusetts General Hospital, heavy drinking increased by 21% during COVID-19 disease.

There are many stakeholders turning to technology as a way to help support healing.


Quit Genius caught the eyes of publishers. In July 2021, the company announced a $ 64 million Series B revenue, which brought the company’s total to $ 77.5 million.

Quit Genius isn’t just about the digital dedication center. Alcohol treatment website Monument closed a $ 10.3 million Series Round fund in January 2021.

Pear Therapeutics has been working on the use of the drug for some time. In 2017, the company landed an FDA De Novo for its DTx for drug use. The following year, Pear obtained a new FDA approval for his opioid -related product.

Related Posts

Leave a Reply

Your email address will not be published.